This company has been marked as potentially delisted and may not be actively trading. NASDAQ:SBPH Spring Bank Pharmaceuticals (SBPH) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Spring Bank Pharmaceuticals Stock (NASDAQ:SBPH) 30 days 90 days 365 days Advanced Chart Get SBPH alerts:Sign Up Key Stats Today's Range N/A50-Day Range$1.21▼$10.3952-Week Range N/AVolumeN/AAverage Volume177,606 shsMarket Capitalization$122.94 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of a range of cancers and inflammatory diseases using its proprietary small molecule nucleotide platform. The company is developing SB 11285, a next-generation immunotherapeutic cyclic dinucleotide for the treatment of selected cancers; novel STING antagonist compounds for the treatment of autoimmune and inflammatory diseases; and novel platform to enable the targeted delivery of payload molecules. It has a collaboration agreement with with Roche to explore the co-administration of SB 11285. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts. Read More Receive SBPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spring Bank Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SBPH Stock News HeadlinesCapital One Bank ReviewOctober 18, 2024 | marketwatch.comDiscover Bank Review (August 2024)August 8, 2024 | marketwatch.com“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.August 28 at 2:00 AM | InvestorPlace (Ad)How many bank holidays are in May? How to get the most from your holiday allowanceMay 10, 2024 | uk.finance.yahoo.comSupermarket May bank holiday opening times 2024 including Tesco, Aldi, Morrisons and moreMay 6, 2024 | mirror.co.ukMWhen will interest rates go down?January 31, 2024 | thetimes.co.ukTBank of Canada expected to 'cautiously' start cutting rates in spring: Deloitte CanadaJanuary 6, 2024 | ca.finance.yahoo.comMan stabbed during street fight in Spring Bank WestSeptember 29, 2023 | hulldailymail.co.ukSee More Headlines SBPH Stock Analysis - Frequently Asked Questions How were Spring Bank Pharmaceuticals' earnings last quarter? Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH) announced its quarterly earnings data on Sunday, November, 8th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by $0.06. When did Spring Bank Pharmaceuticals IPO? Spring Bank Pharmaceuticals (SBPH) raised $14 million in an initial public offering on Friday, May 6th 2016. The company issued 1,100,000 shares at $12.00-$14.00 per share. Dawson James Securities acted as the underwriter for the IPO. What other stocks do shareholders of Spring Bank Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Spring Bank Pharmaceuticals investors own include Intelsat (I), AMC Entertainment (AMC), Bank of America (BAC), Fossil Group (FOSL), Associated British Foods (ABF), Apollo Global Management (APO) and Chaarat Gold (CGH). Company Calendar Last Earnings11/08/2020Today8/28/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:SBPH CIK1566373 Webwww.springbankpharm.com Phone508-473-5993FaxN/AEmployees30Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$24.10 million Net MarginsN/A Pretax MarginN/A Return on Equity-89.89% Return on Assets-52.89% Debt Debt-to-Equity RatioN/A Current Ratio5.11 Quick Ratio5.11 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.16 per share Price / BookN/AMiscellaneous Outstanding Shares17,267,000Free FloatN/AMarket Cap$122.94 million OptionableNot Optionable Beta1.07 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:SBPH) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spring Bank Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spring Bank Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.